Major slash in prices on cancer and diabetic drugs: Pricing Regulatory Authority
National Pharmaceutical Pricing Authority (NPPA) in a statement said cancer and diabetic drugs have seen a major price slash over the years, particularly in the recent past, in the country. Now these drugs are expected to within the reach of a wide population base.
The drug pricing regulator, in a tweet on Monday last, said there has been "significant price reduction" since March 2016. Over the cancer drugs the reduction amounts up to 86 per cent and the reduction up to 42 per cent in major diabetic treating drugs.
The price of Iressa of Astrazeneca Pharma India, one of the major cancer drugs, has been reduced by a whopping Rs 3,977. That constitutes to 86 per cent on the original price Rs 29,259.
The price reduction also covers other important cancer drugs as well. Nanoxel (Rs 1,035) and Frastim (Rs 1,273) have been slashed by 55 per cent and 51 per cent respectively.
The same has been the case with diabetic drugs too. Sun Pharmaceuticals’ Glypride has been priced at Rs 53 – a reduction of about 42 per cent from Rs 91.
The NPPA also said that the price cut also covers the drugs from other pharma firms including Dr Reddy's Lab, Abbot Healthcare, Micro Labs, Dabur India, Lupin and quite a few others.
Image source: Shutterstock
Read More Heath News
Source: Onlymyhealth editorial team Mar 08, 2017
All possible measures have been taken to ensure accuracy, reliability, timeliness and authenticity of the information; however Onlymyhealth.com does not take any liability for the same. Using any information provided by the website is solely at the viewers’ discretion. In case of any medical exigencies/ persistent health issues, we advise you to seek a qualified medical practitioner before putting to use any advice/tips given by our team or any third party in form of answers/comments on the above mentioned website.